# Medicare negotiated prices from 2027: enzalutamide, pomalidomide, palbociclib and acalabrutinib

Source: https://onco.cc/terms/medicare-negotiation-2027-cancer-drugs/  
OnCo record `medicare-negotiation-2027-cancer-drugs` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Of the fifteen drugs whose Medicare-negotiated prices start on 1 January 2027, four are cancer medicines: Xtandi (enzalutamide), Pomalyst (pomalidomide), Ibrance (palbociclib) and Calquence (acalabrutinib).

## Summary

United States, Medicare Drug Price Negotiation Program, second cycle. CMS's data file of 2 November 2026 lists fifteen selected drugs for initial price applicability year 2027, with maximum fair prices effective 1 January 2027. The four cancer medicines and their single maximum fair price per 30-day equivalent supply, as the file gives them:

- Xtandi (enzalutamide): $7,004.00
- Pomalyst (pomalidomide): $8,650.00
- Ibrance (palbociclib): $7,871.00
- Calquence (acalabrutinib): $8,600.00

## Fields

- Kind: Term
- Last checked: 2026-11-04
- Also known as: IPAY 2027; second cycle of Medicare drug price negotiation; Xtandi maximum fair price; Pomalyst maximum fair price; Ibrance maximum fair price; Calquence maximum fair price
- Tags: law; us

## Notes

- Figures copied from the CMS CSV dated 2 November 2026 (rows dated 25 November 2025, type 'New IPAY').

## Sources

- CMS: Negotiation Program selected drug list and maximum fair price data file, 2 November 2026 (ZIP): https://www.cms.gov/files/zip/cms-negotiation-program-selected-drug-list-maximum-fair-price-data-file-20261102.zip
- CMS: Medicare Drug Price Negotiation Program: https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program

## Connected records

- terms: [Inflation Reduction Act 2022: Medicare drug price negotiation](https://onco.cc/terms/inflation-reduction-act/), [Medicare drug price negotiation for 2028: apalutamide, ribociclib, abemaciclib and lenvatinib](https://onco.cc/terms/medicare-negotiation-2028-cancer-drugs/), [Medicare negotiated price for ibrutinib (Imbruvica), first cycle](https://onco.cc/terms/medicare-negotiation-2026-cancer-drug/)
- drugs: [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/), [Enzalutamide](https://onco.cc/drugs/enzalutamide/), [Palbociclib](https://onco.cc/drugs/palbociclib/), [Pomalidomide](https://onco.cc/drugs/pomalidomide/)
- bottlenecks: [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/)

---
JSON: https://onco.cc/api/v1/entities/medicare-negotiation-2027-cancer-drugs.json